The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 912-920

  Kim, Areumnuri ^a,b   Park, Sunhoo ^a,b   Lee, Jung Eun ^a   Jang, Won Suk ^a   Lee, Sun Joo ^a   Kang, Hye Jin ^a   Lee, Seung Sook ^a,b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

Akt; Mantle cell lymphoma; MTOR; NVP BEZ235

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BORTEZOMIB; CYCLIN D1; CYCLIN G1; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; VINCRISTINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; IMIDAZOLES; LYMPHOMA, MANTLE-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PYRAZINES; QUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84862325029     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.010     Document Type: Article

References (46)

1. Campo E., Raffeld M., Jaffe E.S. Mantle-cell lymphoma. Semin Hematol 1999, 36:115-127.
2. Bosch F., Lopez-Guillermo A., Campo E., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
3. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067-2078.
4. Bertoni F., Zucca E., Cotter F.E. Molecular basis of mantle cell lymphoma. Br J Haematol 2004, 124:130-140.
5. Rudelius M., Pittaluga S., Nishizuka S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
6. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A.T., Yoshimura L.C., Ford R.J. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009, 113:4627-4636.
7. Ortega-Paino E., Fransson J., Ek S., Borrebaeck C.A. Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 2008, 111:1617-1624.
8. Boyd R.S., Jukes-Jones R., Walewska R., Brown D., Dyer M.J., Cain K. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009, 8:1501-1515.
9. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
10. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin' lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
11. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
12. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
13. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
14. Dal Col J., Zancai P., Terrin L., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008, 111:5142-5151.
15. Fukumoto S., Hsieh C.M., Maemura K., et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001, 276:17479-17483.
16. Kheirallah S., Caron P., Gross E., et al. Rituximab inhibits B-cell receptor signaling. Blood 2010, 115:985-994.
17. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
18. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
19. Jacinto E., Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4:117-126.
20. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008, 8:393-412.
21. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
22. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009, 315:485-497.
23. Chiarini F., Grimaldi C., Ricci F., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
24. Bhende P.M., Park S.I., Lim M.S., Dittmer D.P., Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010, 24:1781-1784.
25. Herrera V.A., Zeindl-Eberhart E., Jung A., Huber R.M., Bergner A. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res 2011, 31:849-854.
26. Maira S.M., Stauffer F., Brueggen J., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
27. Gera J.F., Mellinghoff I.K., Shi Y., et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004, 279:2737-2746.
28. Brody J., Advani R. Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol 2006, 58:257-265.
29. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
30. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
31. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
32. Rizzieri D.A., Feldman E., Dipersio J.F., et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008, 14:2756-2762.
33. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
34. Howard O.M., Gribben J.G., Neuberg D.S., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
35. Chen L., Willis S.N., Wei A., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005, 17:393-403.
36. Oerlemans R., Franke N.E., Assaraf Y.G., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
37. Shringarpure R., Catley L., Bhole D., et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006, 134:145-156.
38. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005, 4:1533-1540.
39. Ghobrial I.M., McCormick D.J., Kaufmann S.H., et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 2005, 105:3722-3730.
40. Rizzatti E.G., Falcao R.P., Panepucci R.A., et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005, 130:516-526.
41. Psyrri A., Papageorgiou S., Liakata E., et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009, 15:5724-5732.
42. Prasad A., Park I.W., Allen H., et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009, 28:1518-1528.
43. Gills J.J., Dennis P.A. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009, 11:102-110.
44. Gingras A.C., Raught B., Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol 2004, 279:169-197.
45. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
46. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10:457-468.